Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of GS-5745 in moderate to severe ulcerative colitis
NL-OMON40621Phase 1Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of andecaliximab in autoimmune colitis (5 arms), sponsored by Gilead Sciences. Primary endpoints: Safety and tolerability, Pharmacokinetics of GS-5745 and 1 more. Started Jun 2014; status: active, not recruiting.
02
Drugs
andecaliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON40621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40621.